title: [Analysis of infliximab treated pediatric patients with Crohn disease in Hungary].
abstract: Infliximab, the chimeric antibody to tumor necrosis factor-alpha, is indicated for medically refractory pediatric Crohn disease. Aim of our study was to examine the efficacy and side effects of infliximab therapy in Hungarian pediatric patients with Crohn disease since the authorisation of medicine for children to 31.12.2008. 23 children with refractory Crohn disease received infliximab during this period. Induction therapy with 5 mg/kg infliximab at weeks 0, 2, and 6 was introduced. 18 patients (81.8%) achieved clinical response, and 13 patients (59.1%) were in remission at the 6th week of the observation period. The evaluation was based on data of 22 children. Fistula closure rate was 70% at the at the 6th week. Two patients had acute infusion reaction, one had severe anaphilactic reaction after infliximab infusion. Chronic side effects were also observed in three cases. In our study infliximab induction therapy was effective in most pediatric patients with therapy refractory Crohn disease.
authors.affiliation: Semmelweis Egyetem, Altalános Orvostudományi Kar, I. Gyermekgyógyászati Klinika, Budapest, Bókay J. u. 53., 1083. vergab@gyerl.sote.hu
authors.forename: Gábor
authors.initials: G
authors.lastname: Veres
authors.forename: Dolóresz
authors.initials: D
authors.lastname: Szabó
authors.forename: Agnes
authors.initials: A
authors.lastname: Várkonyi
authors.forename: Beáta
authors.initials: B
authors.lastname: Tari
authors.forename: Marianne
authors.initials: M
authors.lastname: Polgár
authors.forename: Judit
authors.initials: J
authors.lastname: B Kovács
authors.forename: Agnes
authors.initials: A
authors.lastname: Horváth
authors.forename: Erika
authors.initials: E
authors.lastname: Tomsits
authors.forename: István
authors.initials: I
authors.lastname: Tokodi
authors.forename: Hedvig
authors.initials: H
authors.lastname: Bodánszky
authors.forename: Antal
authors.initials: A
authors.lastname: Dezsofi
authors.forename: Erzsébet
authors.initials: E
authors.lastname: Szakos
authors.forename: Noémi
authors.initials: N
authors.lastname: Vass
authors.forename: Viktória
authors.initials: V
authors.lastname: Ruszinkó
authors.forename: Márta
authors.initials: M
authors.lastname: Kovács
authors.forename: Katalin Eszter
authors.initials: KE
authors.lastname: Müller
authors.forename: András
authors.initials: A
authors.lastname: Arató
mesh_terms: D000203:Activities of Daily Living; D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006814:Hungary; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D011788:Quality of Life; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab